Evidence map›Paper›PMID 24145167›Full record

ArticleThe Journal of cell biology2013

Soluble oligomers are sufficient for transmission of a yeast prion but do not confer phenotype.

Jennifer E Dulle, Rachel E Bouttenot, Lisa A Underwood, Heather L True

Abstract read
In one paragraph

Article in The Journal of cell biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jennifer E DulleDepartment of Cell Biology and Physiology, Washington University in St. Louis, St. Louis, MO 63110.
Rachel E Bouttenot
Lisa A Underwood
Heather L True

Funding

A PRION REVEALS COMPLEX TRAITS AND PHENOTYPIC DIVERSITYR01GM072778 · NIGMS · WASHINGTON UNIVERSITY · PI TRUE-KROB, HEATHER L · 2005 to 2014
$3.1M
NIGMS NIH HHS GM072778NIGMS NIH HHS R01 GM072778
6 · The paper itself

Abstract

Amyloidogenic proteins aggregate through a self-templating mechanism that likely involves oligomeric or prefibrillar intermediates. For disease-associated amyloidogenic proteins, such intermediates have been suggested to be the primary cause of cellular toxicity. However, isolation and characterization of these oligomeric intermediates has proven difficult, sparking controversy over their biological relevance in disease pathology. Here, we describe an oligomeric species of a yeast prion protein in cells that is sufficient for prion transmission and infectivity. These oligomers differ from the classic prion aggregates in that they are soluble and less resistant to SDS. We found that large, SDS-resistant aggregates were required for the prion phenotype but that soluble, more SDS-sensitive oligomers contained all the information necessary to transmit the prion conformation. Thus, we identified distinct functional requirements of two types of prion species for this endogenous epigenetic element. Furthermore, the nontoxic, self-replicating amyloid conformers of yeast prion proteins have again provided valuable insight into the mechanisms of amyloid formation and propagation in cells.

Indexed as

Epigenesis, GeneticGene Expression Regulation, FungalGenotypeHeat-Shock ProteinsMutationPeptide Termination FactorsPhenotypePrionsProtein ConformationProtein MultimerizationSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSolubilityTime FactorsHeat-Shock ProteinsHsP104 protein, S cerevisiaePeptide Termination FactorsPrionsSaccharomyces cerevisiae ProteinsSUP35 protein, S cerevisiae

Identifiers

PMID24145167
PMCPMC3812976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.